Efficacy of flupirtine on cognitive function in patients with CJD
A double-blind study
Abstract
Background: In cell culture experiments, flupirtine maleate (FLU), a triaminopyridine compound, was able to protect neuronal cells from apoptotic cell death induced by prion protein fragments and β-amyloid peptides. As FLU is a clinically safe drug, the authors started a double-blind placebo-controlled study in patients with Creutzfeldt–Jakob disease (CJD).
Methods: Twenty-eight patients with CJD were randomized to an oral treatment with either FLU (n = 13) or matching placebo (PLA; n = 15). For inclusion and continuing the study, the patients had to achieve at least 50% in two of the subscales of the dementia tests employed. A battery of standardized questionnaires was employed to monitor the progression of the disease. The main outcome variable was the cognitive part of the Alzheimer’s Disease Assessment Scale (ADAS-Cog); the difference between baseline and the best score under treatment was defined as the primary efficacy variable for hypothesis testing.
Results: CJD types were homogeneously distributed among the treatment groups. Patients treated with FLU showed significantly less deterioration in the dementia tests than patients treated with PLA. The mean change in ADAS-Cog (baseline to best) was +8.4 (±15.3) in the FLU group and +20.6 (±15.1) in the PLA group (p = 0.02, one-sided t-test).
Conclusions: FLU has beneficial effects on cognitive function in patients with CJD. These positive results also may suggest a treatment potential of FLU in other neurodegenerative disorders. However, further studies are necessary.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Otto M, Wiltfang J, Cepek L, et al. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt–Jakob disease. Neurology. 2002; 58: 192–197.
2.
Wiltfang J, Esselmann H, Smirnov A, et al. Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease. Ann Neurol. 2003; 54: 263–267.
3.
Hill AF, Butterworth RJ, Joiner S, et al. Investigation of variant Creutzfeldt–Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet. 1999; 353: 183–189.
4.
Brown P. Drug therapy in human and experimental transmissible spongiform encephalopathy. Neurology. 2002; 58: 1720–1725.
5.
Aguzzi A, Glatzel M, Montrasio F, Prinz M, Heppner FL. Interventional strategies against prion diseases. Nat Rev. 2001; 2: 745–749.
6.
Soto C, Saborio GP. Prions: disease propagation and disease therapy by conformational transmission. Trends Mol Med. 2001; 7: 109–114.
7.
Dhar S, Bitting RL, Rylova SN, et al. Flupirtine blocks apoptosis in Batten patient lymphoblasts and in human postmitotic CLN3- and CLN2-deficient neurons. Ann Neurol. 2002; 51: 448–466.
8.
Müller WE, Romero FJ, Perovic S, Pergande G, Pialoglou P. Protection of flupirtine on beta-amyloid-induced apoptosis in neuronal cells in vitro: prevention of amyloid-induced glutathione depletion. J Neurochem. 1997; 68: 2371–2377.
9.
Perovic S, Schröder HC, Pergande G, Ushijima H, Muller WE. Effect of flupirtine on Bcl-2 and glutathione level in neuronal cells treated in vitro with the prion protein fragment (PrP106–126). Exp Neurol. 1997; 147: 518–524.
10.
Parchi P, Giese A, Capellari S, et al. Classification of sporadic Creutzfeldt–Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol. 1999; 46: 224–233.
11.
World Health Organization. Consensus on criteria for sporadic CJD. Geneva: World Health Organization, 1998.
12.
Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry. 1984; 141: 1356–1364.
13.
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatrt Res. 1975; 12: 189–198.
14.
Kessler J, Denzler P, Markowitsch HJ. Demenz-Test. Weinheim: Beltz-Verlag, 1988.
15.
Kretzschmar HA, Ironside JW, DeArmond SJ, Tateishi J. Diagnostic criteria for sporadic Creutzfeldt–Jakob disease. Arch Neurol. 1996; 53: 913–920.
16.
Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. The Tacrine Study Group. JAMA. 1994; 271: 985–991.
17.
O’Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979; 35: 549–556.
18.
Gassen M, Pergande G, Youdim MB. Antioxidant properties of the triaminopyridine, flupirtine. Biochem Pharmacol. 1998; 56: 1323–1329.
Information & Authors
Information
Published In
Copyright
© 2004.
Publication History
Received: April 25, 2003
Accepted: October 28, 2003
Published online: March 8, 2004
Published in print: March 9, 2004
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- A Systematic Review of Sporadic Creutzfeldt-Jakob Disease: Pathogenesis, Diagnosis, and Therapeutic Attempts, Neurology International, 16, 5, (1039-1065), (2024).https://doi.org/10.3390/neurolint16050079
- Perspectives on CRISPR Genome Editing to Prevent Prion Diseases in High-Risk Individuals, Biomedicines, 12, 8, (1725), (2024).https://doi.org/10.3390/biomedicines12081725
- New implications for prion diseases therapy and prophylaxis, Frontiers in Molecular Neuroscience, 17, (2024).https://doi.org/10.3389/fnmol.2024.1324702
- Therapeutic advances in neuroinfectious diseases, Therapeutic Advances in Infectious Disease, 11, (2024).https://doi.org/10.1177/20499361241274246
- Prion diseases motor and neuropsychiatric symptom cluster pharmacotherapy: structured scoping review, BMJ Supportive & Palliative Care, (spcare-2024-005027), (2024).https://doi.org/10.1136/spcare-2024-005027
- Creutzfeldt–Jakob disease and other prion diseases, Nature Reviews Disease Primers, 10, 1, (2024).https://doi.org/10.1038/s41572-024-00497-y
- Creutzfeldt-Jakob-KrankheitCreutzfeldt–Jakob disease, DGNeurologie, (2024).https://doi.org/10.1007/s42451-024-00696-7
- Klinik und Diagnostik humaner spongiformer Enzephalopathien: ein UpdateClinical characteristics and diagnostics of human spongiform encephalopathies: an update, Der Nervenarzt, 95, 4, (376-384), (2024).https://doi.org/10.1007/s00115-024-01644-2
- Neural cell engraftment therapy for sporadic Creutzfeldt-Jakob disease restores neuroelectrophysiological parameters in a cerebral organoid model, Stem Cell Research & Therapy, 14, 1, (2023).https://doi.org/10.1186/s13287-023-03591-2
- Treating cognitive impairments in primary central nervous system infections: A systematic review of pharmacological interventions, Medicine, 102, 28, (e34151), (2023).https://doi.org/10.1097/MD.0000000000034151
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.